Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.
November 20, 2023 Please see attachment. Contact informationInvestor RelationsAnders Mohr Christensen +45 2515 2364dkamc@chr-hansen.comPress RelationsSanne Seyer-Hansen +45 6038 6207dksash@chr-hansen.comAttachment 2023_Update on the merger approval process for the combination of Novozymes and Chr. Hansen
Comunicato Precedente
Comunicato Successivo
November 20, 2023
Please see attachment.
Contact information
Investor Relations
Anders Mohr Christensen
+45 2515 2364
dkamc@chr-hansen.com
Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com
Attachment
- 2023_Update on the merger approval process for the combination of Novozymes and Chr. Hansen
Per maggiori informazioni
Sito Web
chr-hansen.com
Ufficio Stampa
Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
;
